Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18838570 | 0.86 | NR1H2 (0.41) | GPR119NR1H2NR1H3PTGER4HRH3 | |
| SCHEMBL18838576 | 0.86 | GPR119 (0.39) | GPR119NR1H2NR1H3PTGER4HRH3 | |
| Hydrochloric Acid SCHEMBL18838568 | 0.85 | GPR119 (0.38) | GPR119NR1H2NR1H3PTGER4HRH3 | |
| Hydrochloric Acid SCHEMBL18838569 | 0.85 | GPR119 (0.38) | GPR119NR1H2NR1H3PTGER4HRH3 | |
| SCHEMBL18838593 | 0.83 | GPR119 (0.42) | GPR119NR1H2NR1H3PGRNR3C2 | |
| SCHEMBL22368375 | 0.82 | NR1H2 (0.44) | GPR119NR1H2NR1H3HRH3 | |
| SCHEMBL18872827 | 0.81 | NR1H2 (0.66) | GPR119NR1H2NR1H3HRH3 | |
| SCHEMBL18838560 | 0.81 | NR1H2 (0.66) | GPR119NR1H2NR1H3HRH3 | |
| SCHEMBL23838140 | 0.78 | NR1H2 (0.42) | GPR119NR1H2NR1H3PTGER4HRH3 | |
| SCHEMBL18921631 | 0.76 | GPR119 (0.37) | GPR119PTGER4HRH3PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3373933-B1 | BISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20180305332-A1 | Bispiperidinyl Derivatives as Liver X Receptor Beta Agonists, Compositions, and Their Use | MERCK SHARP & DOHME CORP. (US) | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305332-A1 | Bispiperidinyl Derivatives as Liver X Receptor Beta Agonists, Compositions, and Their Use | NR1H2, NR1H3, NR1H4 | GPR119 8/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.